142 related articles for article (PubMed ID: 30771875)
1. Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know?
Galicia-Vázquez G; Aloyz R
Crit Rev Oncol Hematol; 2019 Feb; 134():65-70. PubMed ID: 30771875
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes.
Galicia-Vázquez G; Aloyz R
Front Oncol; 2018; 8():411. PubMed ID: 30319974
[TBL] [Abstract][Full Text] [Related]
3. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.
Martinez Marignac VL; Smith S; Toban N; Bazile M; Aloyz R
Oncotarget; 2013 Dec; 4(12):2550-66. PubMed ID: 24334291
[TBL] [Abstract][Full Text] [Related]
4. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.
Liu PP; Liu J; Jiang WQ; Carew JS; Ogasawara MA; Pelicano H; Croce CM; Estrov Z; Xu RH; Keating MJ; Huang P
Oncogene; 2016 Oct; 35(43):5663-5673. PubMed ID: 27065330
[TBL] [Abstract][Full Text] [Related]
5. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
6. ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia.
Tannoury M; Ayoub M; Dehgane L; Nemazanyy I; Dubois K; Izabelle C; Brousse A; Roos-Weil D; Maloum K; Merle-Béral H; Bauvois B; Saubamea B; Chapiro E; Nguyen-Khac F; Garnier D; Susin SA
Leukemia; 2024 Feb; 38(2):302-317. PubMed ID: 38057495
[TBL] [Abstract][Full Text] [Related]
7. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia.
Jitschin R; Hofmann AD; Bruns H; Giessl A; Bricks J; Berger J; Saul D; Eckart MJ; Mackensen A; Mougiakakos D
Blood; 2014 Apr; 123(17):2663-72. PubMed ID: 24553174
[TBL] [Abstract][Full Text] [Related]
9. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.
Vangapandu HV; Ayres ML; Bristow CA; Wierda WG; Keating MJ; Balakrishnan K; Stellrecht CM; Gandhi V
Neoplasia; 2017 Oct; 19(10):762-771. PubMed ID: 28863345
[TBL] [Abstract][Full Text] [Related]
10. Metabolism pathways in chronic lymphocytic leukemia.
Rozovski U; Hazan-Halevy I; Barzilai M; Keating MJ; Estrov Z
Leuk Lymphoma; 2016; 57(4):758-65. PubMed ID: 26643954
[TBL] [Abstract][Full Text] [Related]
11. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
12. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
Carew JS; Nawrocki ST; Xu RH; Dunner K; McConkey DJ; Wierda WG; Keating MJ; Huang P
Leukemia; 2004 Dec; 18(12):1934-40. PubMed ID: 15483672
[TBL] [Abstract][Full Text] [Related]
13. Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling.
Jitschin R; Braun M; Qorraj M; Saul D; Le Blanc K; Zenz T; Mougiakakos D
Blood; 2015 May; 125(22):3432-6. PubMed ID: 25778534
[TBL] [Abstract][Full Text] [Related]
14. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
Giannoni P; Cutrona G; Totero D
Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
[TBL] [Abstract][Full Text] [Related]
15. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
[TBL] [Abstract][Full Text] [Related]
16. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.
Chen SS; Chang BY; Chang S; Tong T; Ham S; Sherry B; Burger JA; Rai KR; Chiorazzi N
Leukemia; 2016 Apr; 30(4):833-43. PubMed ID: 26582643
[TBL] [Abstract][Full Text] [Related]
17. PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions.
Li YJ; Sun L; Shi Y; Wang G; Wang X; Dunn SE; Iorio C; Screaton RA; Spaner DE
Leukemia; 2017 Sep; 31(9):1905-1914. PubMed ID: 28050012
[TBL] [Abstract][Full Text] [Related]
18. Selective Anticancer Activity of Acacetin Against Chronic Lymphocytic Leukemia Using Both In Vivo and In Vitro Methods: Key Role of Oxidative Stress and Cancerous Mitochondria.
Salimi A; Roudkenar MH; Sadeghi L; Mohseni A; Seydi E; Pirahmadi N; Pourahmad J
Nutr Cancer; 2016; 68(8):1404-1416. PubMed ID: 27779444
[TBL] [Abstract][Full Text] [Related]
19. Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL.
Halina A; Artur P; Barbara MK; Joanna S; Anna D
Folia Histochem Cytobiol; 2010 Dec; 48(4):534-41. PubMed ID: 21478095
[TBL] [Abstract][Full Text] [Related]
20. Critical molecular pathways in CLL therapy.
Ferrer G; Montserrat E
Mol Med; 2018 Mar; 24(1):9. PubMed ID: 30134797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
